Cell News and Research

RSS

NFKB1 gene variant may reduce risk of lung cancer

A variant in a gene involved with inflammation and the immune response is linked with a decreased risk of lung cancer. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the American Cancer Society. The results add to the growing body of literature implicating these processes in the development of lung cancer.

8 Oct 2012

Researchers decipher how AP-1 gene regulator controls survival of liver tumor-initiating cells

Researchers headed by Erwin Wagner, the Director of the BBVA Foundation-CNIO Cancer Cell Biology Programme at the Spanish National Cancer Research Centre (CNIO), have deciphered how a stress-inducible gene regulator, AP-1, controls the survival of liver tumor-initiating cells. These results, published in the online edition of Nature Cell Biology, could provide new preventive strategies and identify potentially targetable molecules to prevent liver cancer.

8 Oct 2012

Progenra’s USP7 and USP47 exert non-overlapping anticancer cell effects

Researchers at Progenra, Inc. announce the advanced online publication of the article "Selective Dual Inhibitors of the Cancer-related Deubiquitylating Proteases USP7 and USP47." The new article presents evidence of a therapeutic benefit resulting from dual inhibition of USP7 and a related enzyme, USP47.

8 Oct 2012

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it is presenting an update on its Feline Immunodeficiency Virus (FIV) therapeutic antibody program at the 19th West Coast Retrovirus meeting in Palm Springs, California.

8 Oct 2012

FDA clears Fenwal's new plasma products

Fenwal Inc., a global leader specializing in separation technologies for blood and cell collection and therapy, announced today it has received clearance from the U.S. Food and Drug Administration for two new indications for collection of plasma products on the Fenwal Alyx and Amicus systems.

8 Oct 2012

Researchers perfect map of vision in the brain based upon brain structure

Nearly 100 years after a British neurologist first mapped the blind spots caused by missile wounds to the brains of soldiers, Perelman School of Medicine researchers at the University of Pennsylvania have perfected his map using modern-day technology. Their results create a map of vision in the brain based upon an individual's brain structure, even for people who cannot see.

6 Oct 2012

Gene-silencing mechanism may occur later in life and lead to cancer

There are some genes that are only activated in the very first days of an embryo's existence. Once they have accomplished their task, they are shut down forever, unlike most of our genes, which remain active throughout our lives. EPFL scientists have unveiled part of this strange mechanism. The same process, accidentally initiated later in life, could be responsible for many kinds of cancer.

6 Oct 2012

Study demonstrates efficacy of genotyping technology in identifying source of clinic infection outbreak

Researchers from East Carolina University used a new technique of genotyping to identify the source of a hematology clinic outbreak of Mycobacterium mucogenicum, a gram-positive, acid-fast bacteria found in tap water. This is the first outbreak of M. mucogenicum in an ambulatory care setting; five other outbreaks have been reported in hospital settings since 1995.

6 Oct 2012

Without B-Raf and C-Raf proteins mice's fur turns white

These proteins are required for melanocyte stem cell self-maintenance and, as such, correct pigmentation throughout the mice's life span. Without these two proteins, the mice's fur turns white. Their research is published in the review 'Cell Report' and paves the way for serious possibilities in terms of stopping the formation of melanomas, tumours that originate from melanocyte cells.

6 Oct 2012

NIH awards $2.1M grant to study possible ways to fight cancer

A professor with the University of Houston Cullen College of Engineering has won a $2.1 million grant to study the best ways to modify human immune cells to fight against cancer.

6 Oct 2012

BUSM leads genome-wide evaluation of genetic variants associated with Parkinson's disease

Boston University School of Medicine investigators have led the first genome-wide evaluation of genetic variants associated with Parkinson's disease (PD). The study, which is published online in PLOS ONE, points to the involvement of specific genes and alterations in their expression as influencing the risk for developing PD.

6 Oct 2012

Researchers discover brain mechanism responsible for sensation of nausea

Nausea is a common and distressing side effect of many drugs and treatments. Unlike vomiting, nausea is not well understood, but new research by University of Guelph scientists may soon change that.

6 Oct 2012

Nanoprobe inventor awarded NJIT Board of Overseers Excellence in Research Prize and Medal

NJIT Research Professor Reginald C. Farrow, PhD, who with his research team have discovered how to make nanoscale arrays of the world's smallest probe for investigating the electrical properties of individual living cells was awarded yesterday, Oct. 4, 2012, the NJIT Board of Overseers Excellence in Research Prize and Medal. This prize is the most prestigious research award at NJIT. It is the fifth time the award has been made.

6 Oct 2012

Nelfinavir inhibits growth of HER2-positive tumors

The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute.

6 Oct 2012

Progress toward preventing initial and recurrent episodes of C. diff infection

Surgeons are making progress toward preventing initial and recurrent episodes of clostridium difficile colitis (C. difficile or C. diff), a vicious bacterial infection that is estimated to affect about 336,000 people each year, typically patients on antibiotics.

6 Oct 2012

DPP-inhibitors reduce cardiovascular events in diabetes patients

Type 2 diabetes patients who are treated with dipeptidyl peptidase-4 inhibitors have a significantly reduced risk for cardiovascular events, particularly myocardial infarction, compared with their peers who take placebo or other drugs, results of a meta-analysis show.

5 Oct 2012

RXi receives SBIR grant to enable discovery and preclinical development of sd-rxRNAs

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it was awarded a Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH).

5 Oct 2012

Mouse genome consists of 10-nm chromatin fibres

Scientists in Canada and the United States have used three-dimensional imaging techniques to settle a long-standing debate about how DNA and structural proteins are packaged into chromatin fibres. The researchers, whose findings are published in EMBO reports, reveal that the mouse genome consists of 10-nm chromatin fibres but did not find evidence for the wider 30-nm fibres that were previously thought to be important components of the DNA architecture.

5 Oct 2012

Researchers identify genetic risk allele for uterine fibroids

Uterine fibroids are the most common type of pelvic tumors in women and are the leading cause of hysterectomy in the United States. Researchers from Brigham and Women's Hospital (BWH) are the first to discover a genetic risk allele (an alternative form of a gene) for uterine fibroids in white women using an unbiased, genome-wide approach.

5 Oct 2012

Contract Manufacturing Offering introduced to the biopharmaceutical market by Olympus Biotech

Olympus Biotech, an Olympus Corporation company, today announced its new Contract Manufacturing Offering (CMO) at its state-of-the-art facility in Lebanon, New Hampshire.

From Evident Corporation - Life Sciences 5 Oct 2012